Nurix Therapeutics, Inc. (NRIX)
Automate Your Wheel Strategy on NRIX
With Tiblio's Option Bot, you can configure your own wheel strategy including NRIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NRIX
- Rev/Share 0.6752
- Book/Share 5.7553
- PB 2.019
- Debt/Equity 0.0554
- CurrentRatio 6.2642
- ROIC -0.4342
- MktCap 885857672.0
- FreeCF/Share -2.4125
- PFCF -4.3943
- PE -4.6592
- Debt/Assets 0.0433
- DivYield 0
- ROE -0.4749
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NRIX | Leerink Partners | -- | Market Perform | -- | $16 | March 17, 2025 |
| Initiation | NRIX | BTIG Research | -- | Buy | -- | $35 | Dec. 10, 2024 |
| Initiation | NRIX | BMO Capital Markets | -- | Outperform | -- | $35 | Dec. 6, 2024 |
| Initiation | NRIX | Jefferies | -- | Buy | -- | $41 | Oct. 11, 2024 |
| Resumed | NRIX | Robert W. Baird | -- | Outperform | -- | $26 | Sept. 6, 2024 |
News
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress in Milan, Italy.
Read More
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Sanofi Exercises License Extension Option to Nurix's STAT6 Program
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and retains an option to co-develop and co-promote in the U.S. SAN FRANCISCO, June 02, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), …
Read More
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences.
Read More
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour
Read More
Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on February 11, 2025, the company granted inducement awards to nine new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in …
Read More
About Nurix Therapeutics, Inc. (NRIX)
- IPO Date 2020-07-24
- Website https://www.nurixtx.com
- Industry Biotechnology
- CEO Dr. Arthur T. Sands M.D., Ph.D.
- Employees 286